AU1936301A - Targeted methods of drug screening using co-culture methods - Google Patents

Targeted methods of drug screening using co-culture methods

Info

Publication number
AU1936301A
AU1936301A AU19363/01A AU1936301A AU1936301A AU 1936301 A AU1936301 A AU 1936301A AU 19363/01 A AU19363/01 A AU 19363/01A AU 1936301 A AU1936301 A AU 1936301A AU 1936301 A AU1936301 A AU 1936301A
Authority
AU
Australia
Prior art keywords
methods
gene
cell
target gene
molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU19363/01A
Inventor
Matthew Ashby
Daniel D. Shoemaker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rosetta Inpharmatics LLC
Original Assignee
Rosetta Inpharmatics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rosetta Inpharmatics LLC filed Critical Rosetta Inpharmatics LLC
Publication of AU1936301A publication Critical patent/AU1936301A/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The present invention provides methods of screening for a molecule that inhibits the expression or activity of a protein encoded by a target gene which affects the fitness of a cell. The methods are based on a co-culture assay, and entail culturing together two cell populations, each of which is a population of identical cells, of the same species that differs substantially only in the expression or activity of the gene to be targeted or its encoded protein and the presence or absence of a reporter gene. The screen can be applied to cultured cells, unicellular and multicellular organisms. Manipulating the expression or activity of the target gene sensitizes the host to a molecule which inhibits the target gene or its encoded protein such that the cell or organism comprising the manipulated target gene grows at a different rate from the cell or organism comprising the unmanipulated gene in response to exposure to the molecule. The methods of the invention can be used for identifying drugs, proteins or any other molecules that inhibit the function of proteins encoded by target genes.
AU19363/01A 1999-12-03 2000-11-30 Targeted methods of drug screening using co-culture methods Abandoned AU1936301A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09454889 1999-12-03
US09/454,889 US6518035B1 (en) 1998-06-02 1999-12-03 Targeted methods of drug screening using co-culture methods
PCT/US2000/032624 WO2001040518A1 (en) 1999-12-03 2000-11-30 Targeted methods of drug screening using co-culture methods

Publications (1)

Publication Number Publication Date
AU1936301A true AU1936301A (en) 2001-06-12

Family

ID=23806481

Family Applications (1)

Application Number Title Priority Date Filing Date
AU19363/01A Abandoned AU1936301A (en) 1999-12-03 2000-11-30 Targeted methods of drug screening using co-culture methods

Country Status (9)

Country Link
US (1) US6518035B1 (en)
EP (1) EP1235935B1 (en)
JP (1) JP4718082B2 (en)
AT (1) ATE357537T1 (en)
AU (1) AU1936301A (en)
CA (1) CA2393360C (en)
DE (1) DE60034059T2 (en)
ES (1) ES2283334T3 (en)
WO (1) WO2001040518A1 (en)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6656695B2 (en) * 2000-03-06 2003-12-02 Bioseek, Inc. Biomap characterization of biologically active agents
US20020049544A1 (en) * 2000-06-23 2002-04-25 Cytokinetics, Inc. Image analysis for phenotyping sets of mutant cells
WO2002090927A2 (en) * 2001-05-04 2002-11-14 Axiom Biotechnologies, Inc. Matrix assays in genomically indexed cells
US6894205B2 (en) * 2001-06-22 2005-05-17 Vanderbilt University Assay for toxin induced neuronal degeneration and viability in C. elegans
US6977152B2 (en) * 2001-09-07 2005-12-20 Virtual Arrays, Inc. Biological assays using coded RNA reporters
US20030069256A1 (en) * 2001-09-25 2003-04-10 Torrance Christopher J. Use of isogenic human cancer cells for high-throughput screening and drug discovery
AU2002353704A1 (en) 2001-11-21 2003-06-10 Bioimics Ab Method and kit for detection of novel pathogen inhibitors
DE10261834A1 (en) * 2002-12-20 2004-07-08 Phenion Gmbh & Co. Kg High-throughput suitable screening process for the identification of active substances
WO2005020886A2 (en) * 2003-06-27 2005-03-10 New England Biolabs, Inc. Identification and use of cofactor independent phosphoglycerate mutase as a drug target
EP1646926A2 (en) * 2003-07-18 2006-04-19 Cytokinetics, Inc. Characterizing biological stimuli by response curves
US7150969B2 (en) * 2004-06-04 2006-12-19 Rosetta Inpharmatics Llc Alternatively spliced isoform of acetyl-CoA carboxylase 2 (ACC2)
WO2007008609A2 (en) 2005-07-07 2007-01-18 The Regents Of The University Of California Methods and apparatus for cell culture array
US9354156B2 (en) 2007-02-08 2016-05-31 Emd Millipore Corporation Microfluidic particle analysis method, device and system
US9637715B2 (en) 2005-07-07 2017-05-02 Emd Millipore Corporation Cell culture and invasion assay method and system
US8257964B2 (en) 2006-01-04 2012-09-04 Cell ASIC Microwell cell-culture device and fabrication method
US9388374B2 (en) 2005-07-07 2016-07-12 Emd Millipore Corporation Microfluidic cell culture systems
US7745209B2 (en) 2005-07-26 2010-06-29 Corning Incorporated Multilayered cell culture apparatus
US7745210B2 (en) * 2006-06-30 2010-06-29 Corning Incorporated Fluid flow diverter for cell culture vessel
WO2008073900A1 (en) * 2006-12-08 2008-06-19 Worcester Polytechnic Institute (Wpi) Targets, including yap1, for antifungal drug discovery and therapy
US7897379B2 (en) * 2007-02-26 2011-03-01 Corning Incorporated Device and method for reducing bubble formation in cell culture
US9309491B2 (en) * 2007-05-29 2016-04-12 Corning Incorporated Cell culture apparatus for co-culture of cells
GB2451287A (en) * 2007-07-26 2009-01-28 Envirogene Ltd Identification of hydrocarbon deposits through detection of a microbial polynucleotide
ES2882661T3 (en) 2008-01-03 2021-12-02 Emd Millipore Corp Cell culture matrix system for automated assays and methods of operation and manufacturing thereof
US9353342B2 (en) 2010-01-21 2016-05-31 Emd Millipore Corporation Cell culture and gradient migration assay methods and devices
US10526572B2 (en) 2011-04-01 2020-01-07 EMD Millipore Corporaticn Cell culture and invasion assay method and system
SG10201609393QA (en) 2011-12-03 2017-01-27 Emd Millipore Corp Micro-incubation systems for microfluidic cell culture and methods
WO2017079699A1 (en) * 2015-11-04 2017-05-11 The Broad Institute, Inc. Multiplex high-resolution detection of micro-organism strains, related kits, diagnostics methods and screening assays
KR102127949B1 (en) * 2018-11-16 2020-06-29 충북대학교 산학협력단 Dna aptamer specifically binding to erg11 protein and using the same
CA3155166A1 (en) 2019-09-24 2021-04-01 Universite De Geneve Method to independently analyze multiple biological processes in encapsulated 3d cell co-cultures
CN113130000B (en) * 2021-03-22 2022-09-16 同济大学 Method for screening artemisinin antimalarial target gene
JP2024529939A (en) * 2021-07-23 2024-08-14 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Methods and model systems for evaluating therapeutic properties of candidate agents, and related computer readable media and systems

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4980281A (en) 1988-02-10 1990-12-25 Housey Gerard M Method of screening for protein inhibitors and activators
WO1995006132A2 (en) 1993-08-27 1995-03-02 Myco Pharmaceuticals, Incorporated Identifying biologically active agents through culture color change
EP0679716A4 (en) 1993-11-12 1999-06-09 Kenichi Matsubara Gene signature.
JP2002509428A (en) 1996-08-07 2002-03-26 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア AFC1 and RCE1: isoprenylated CAAX processing enzyme
WO1998054333A2 (en) 1997-06-02 1998-12-03 Acacia Biosciences Inc. Mammalian caax processing enzymes
CA2234418A1 (en) 1997-06-24 1998-12-24 Smithkline Beecham Corporation Human afc1
CA2234402A1 (en) 1997-06-24 1998-12-24 Smithkline Beecham Corporation Human rce1
US6046002A (en) 1998-01-05 2000-04-04 The Board Of Trustees Of The Leland Stanford Junior University Highly parallel and sensitive method for identifying drugs and drug targets

Also Published As

Publication number Publication date
CA2393360A1 (en) 2001-06-07
EP1235935A1 (en) 2002-09-04
DE60034059D1 (en) 2007-05-03
ATE357537T1 (en) 2007-04-15
CA2393360C (en) 2013-01-08
JP4718082B2 (en) 2011-07-06
EP1235935B1 (en) 2007-03-21
US6518035B1 (en) 2003-02-11
ES2283334T3 (en) 2007-11-01
WO2001040518A1 (en) 2001-06-07
JP2003517308A (en) 2003-05-27
EP1235935A4 (en) 2004-10-20
DE60034059T2 (en) 2007-12-13

Similar Documents

Publication Publication Date Title
AU1936301A (en) Targeted methods of drug screening using co-culture methods
Müller et al. Origin and analysis of microbial population heterogeneity in bioprocesses
Lee et al. Single C-to-T substitution using engineered APOBEC3G-nCas9 base editors with minimum genome-and transcriptome-wide off-target effects
Nath et al. Comparative analysis reveals a role for TGF-β in shaping the residency-related transcriptional signature in tissue-resident memory CD8+ T cells
Yang et al. A novel transformation suppressor, Pdcd4, inhibits AP-1 transactivation but not NF-κB or ODC transactivation
Vahedi et al. STATs shape the active enhancer landscape of T cell populations
Freimer et al. Systematic discovery and perturbation of regulatory genes in human T cells reveals the architecture of immune networks
Tabach et al. The promoters of human cell cycle genes integrate signals from two tumor suppressive pathways during cellular transformation
Brosh et al. A versatile platform for locus-scale genome rewriting and verification
Qi et al. Dynamic CTCF binding directly mediates interactions among cis-regulatory elements essential for hematopoiesis
Rendueles et al. Evolution by flight and fight: diverse mechanisms of adaptation by actively motile microbes
Bloch et al. Factors affecting the loss of MED12-mutated leiomyoma cells during in vitro growth
Okochi et al. Cell behavior observation and gene expression analysis of melanoma associated with stromal fibroblasts in a three‐dimensional magnetic cell culture array
Storz et al. Functional genomic insights into regulatory mechanisms of high-altitude adaptation
Gu et al. Establishment and characterization of an immortalized renal cell line of the Chinese tree shrew (Tupaia belangeri chinesis)
Li et al. Nitrilase-activatable noncanonical amino acid precursors for cell-selective metabolic labeling of proteomes
Fardoos et al. HIV specific CD8+ TRM-like cells in tonsils express exhaustive signatures in the absence of natural HIV control
Ding et al. Secretome screening reveals immunomodulating functions of IFNα-7, PAP and GDF-7 on regulatory T-cells
Cohen Mitochondria and Chloroplasts Revisited: Recent studies on these cellular organelles suggest approaches to the problems of their origins
Heng The genomic landscape of cancers
Biswas et al. 3D spheroid culturing of Astyanax mexicanus liver‐derived cell lines recapitulates distinct transcriptomic and metabolic states of in vivo tissue environment
Oren et al. Cycling cancer persister cells arise from lineages with distinct transcriptional and metabolic programs
Nakaya et al. Enrichment of stem-like cell population comprises transformation ability of Epstein–Barr virus latent membrane protein 2A for non-transformed cells
Gate et al. Mapping gene regulatory networks of primary CD4+ T cells using single-cell genomics and genome engineering
Zur Bruegge et al. Intestinal organoids in colitis research: focusing on variability and cryopreservation

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase